Natalie Brown

Natalie Brown supports the Food and Drug Administration’s Office of Acquisition and Grant Services in executing mission-critical procurement activities that sustain the agency’s regulatory science infrastructure. She manages acquisitions for high-precision analytical instrumentation, laboratory testing services, and scientific support systems essential to ensuring the safety and efficacy of pharmaceuticals, biologics, and medical devices. Her work directly enables the FDA’s scientific and regulatory operations by securing specialized technical services and equipment that underpin public health oversight. She routinely handles complex contract actions under FAR Part 16, including cost-reimbursement and time-and-materials arrangements, with a focus on mission-critical, non-commoditized procurements. Brown maintains strategic relationships with key contractors including Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc., and Progenics Pharmaceuticals Inc., partnering primarily with niche scientific service providers and specialized analytical laboratories. These vendor relationships reflect a preference for firms with deep domain expertise in toxicology, clinical research support, and regulated laboratory operations. Her contracting approach emphasizes technical qualification, compliance with GxP standards, and proven track records in FDA-regulated environments, fostering long-term, performance-based partnerships rather than transactional engagements. Her procurement patterns show a strong commitment to small business participation, with 44.4% of awards designated as total small business set-asides under FAR 19.5. While no set-aside preferences for 8(a), HUBZone, or SDVOSB are dominant, her portfolio consistently prioritizes small businesses with specialized scientific capabilities, aligning with the FDA’s broader goal of expanding access to innovative, agile service providers in regulated science. Brown’s primary procurement focus lies in NAICS 541380 (testing laboratories) and 334516 (analytical instrument manufacturing), reflecting her expertise in acquiring advanced chromatography systems, mass spectrometers, and validated lab services. She also procures supporting services in satellite telecommunications and professional training, ensuring comprehensive technical infrastructure for FDA’s scientific workforce and regulatory decision-making.